Overview
This a single-center, prospective, exploratory study. Patients with metastatic
castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled
prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los
Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron
emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT
(18F-DCFPyL
(2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioi
c acid)positron emission tomography/computed tomography , as per standard of care in our
institution. All patients further undergo eventual follow-up prostate-specific membrane
antigen positron emission tomography (PSMA PET) after the 2nd, 4th, and 6th LuPSMA RLT
cycle. In this prospective study, an18F-Fluciclovine positron emission
tomography/computed tomography ( Axumin PET/CT )will be additionally obtained at baseline
(pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles. Axumin PET/CT will be
acquired within 7 days from the PSMA PET.
This study is open to Veterans only.
Description
The imaging analysis will consist in obtaining quantitative measurements of lesion uptake on the pre- and post-LuPSMA RLT (lesion and whole-body SUVmax, SUVmean and tumor volume) at each time point on all PET/CT scans. PET metrics at the lesion- and whole-body level will be compared among different PET radiopharmaceuticals at the same time point, and changes over time will be assessed.
All patients will be followed-up at our institution and clinical outcome will be correlated to the imaging analysis assessment.
Eligibility
Inclusion Criteria:
- Patients with mCRPC scheduled to undergo LuPSMA RLT.
- Willingness to undergo multiple serial PET/CT scans pre- and post-LuPSMA RLT.
- Ability of providing written informed consent.
Exclusion Criteria:
- Less than 18 years-old at the time of radiopharmaceutical administration.
- Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.
- Contraindications to LuPSMA RLT.